Category - Developments

Developments

Precipio launches HemeScreen AML

Precipio (NASDAQ:PRPO) launched its HemeScreen acute myeloid leukemia (AML) panel, which tests for the presence of mutations in certain genes to help develop a treatment plan for patients. The company noted that AML...

September 22, 2020

Developments

Crinetics gets FDA rare pediatric disease designation for congenital hyperinsulinism

The FDA granted Crinetics Pharmaceuticals’ (NASDAQ:CRNX) CRN04777 rare pediatric disease designation for the treatment of congenital hyperinsulinism. Congenital hyperinsulinism occurs when infants are born with life...

September 21, 2020

Developments

FDA clears Acutus’ AcQMap catheter

The FDA cleared Acutus Medical’s (NASDAQ:AFIB) AcQMap, a 3D mapping and navigation catheter designed to be inserted into the left and right atrium. In addition to cardiac activation mapping, the AcQMap catheter can...

September 17, 2020

Developments

Zynerba Pharma Zygel gets FDA orphan drug designation for 22q deletion syndrome

Zynerba Pharma’s (NASDAQ:ZYNE) Zygel was granted FDA orphan drug designation for the treatment of 22q11.2 deletion syndrome. Also known as DiGeorge syndrome, 22q11.2 deletion syndrome is caused by a deletion of a small...

September 17, 2020

Developments

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 demonstrated positive activity against SARS-CoV-2 in a preclinical study conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Conducted under...

September 17, 2020

Developments

Arrowhead reports positive interim results from Phase 2 alpha-1 liver disease trial

Arrowhead Pharma (NASDAQ:ARWR) reported positive 24-week data from its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. ARO-ATT is a subcutaneously...

September 16, 2020

Developments

Aerpio completes enrollment in Phase 2 glaucoma trial

Aerpio Pharma (NASDAQ:ARPO) completed enrollment in its Phase 2 trial evaluating razuprotafib for the treatment of elevated intraocular pressure (IOP). The study enrolled some 195 patients with elevated IOP associated...

September 15, 2020

Developments

Kiniksa mavrilimumab gets FDA orphan drug designation for giant cell arteritis

Kiniksa Pharma’s (NASDAQ:KNSA) mavrilimumab received FDA orphan drug designation for the treatment of giant cell arteritis (GCA). GCA is a chronic inflammatory disease of medium-to-large arteries, which can result in...

September 15, 2020

Developments

Titan Pharma Probuphine commercialization partner inks European distribution agreement

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine commercialization partner, Molteni, signed an exclusive European distribution agreement with Accord Healthcare Europe for the commercialization of Sixmo, the brand name...

September 15, 2020

Developments

Frequency Therapeutics reports positive results from hearing loss study

Frequency Therapeutics (NASDAQ:FREQ) reported results from its Phase 2a clinical study of FX-322 for the treatment of sensorineural hearing loss (SNHL). The study follows a Phase 1/2 trial that demonstrated...

September 14, 2020

Category - Developments

Subscribe